KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT-J trial.

Koutaro Yokote, Yasushi Fukushima, Tomotaka Shingaki, Tomonori Oura, Wataru Ogawa

Diabetes Obes Metab 28(2) 1278-1287

PMID41290555
PMCIDPMC12803658
DOI10.1111/dom.70315
发表日期2025-11-25
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIGURE 1:森林图/亚组分析图;FIGURE 2:森林图/亚组分析图;FIGURE 3:森林图/亚组分析图。
摘要

摘要

AIMS: This analysis aimed to assess the influence of selected baseline factors on tirzepatide treatment response in Japanese patients with obesity disease. MATERIALS AND METHODS: This was a prespecified subgroup analysis of the SURMOUNT-J trial. Japanese adults with obesity disease, excluding diabetes, were randomised 1:1:1 to receive once-weekly subcutaneous tirzepatide 10 mg, tirzepatide 15 mg, or placebo. Key safety and efficacy outcomes at week 72 were analysed by baseline characteristics, including sex, age (<65, ≥65 years), and body mass index (BMI; <35 kg/m2, ≥35 kg/m2). Post hoc analyses were conducted to examine cardiometabolic parameters by subgroup. RESULTS: Overall, 225 participants were examined (tirzepatide 10 mg: n = 73; tirzepatide 15 mg: n = 77; placebo: n = 75). Weight reduction at week 72 was generally similar across subgroups. Numerically greater reductions in percent body weight at week 72 were observed in females (estimated treatment differences: 10 mg, -17.5%; 15 mg, -24.9%) compared with males (10 mg, -15.1%; 15 mg, -18.1%) and in the BMI <35 kg/m2 subgroup (10 mg, -18.7%; 15 mg, -21.7%) compared with the BMI ≥35 kg/m2 subgroup (10 mg, -11.7%; 15 mg, -20.4%) with tirzepatide compared with placebo. Higher proportions of participants achieved ≥5% weight reduction following week 72 of tirzepatide (86%-100%) compared with placebo (18%-30%) across subgroups, and all subgroups showed improvements in cardiometabolic parameters with tirzepatide. Safety profiles did not substantially differ by subgroup. CONCLUSIONS: These results suggest that tailored interventions such as tirzepatide dosage adjustments may help optimise the treatment management of Japanese patients with obesity disease. STUDY REGISTRATION: ClinicalTrials.gov, NCT04844918.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1Estimated treatment differences in percentage change in body weight from baseline to week 72 by baseline factors. Data are shown as LSM treatment difference (95% CI) for tirzepatide 10 and 15 mg compared to placebo, as estimated from MMRM by treatment and visit. The p values correspond to the interaction p values from MMRM (treatment by subgroup) at week 72. BMI, body mass index; CI, confidence interval; LSM, least squares mean; MMRM, mixed model for repeated measures.
非 KM Figure
FIGURE 2Percentage change in body weight for individual participants. Percentage weight change from baseline at week 72 for individual participants in the (A) age; (B) sex; and (C) BMI subgroups. Participants were ordered by the rank of percent changes within each subgroup arm. BMI, body mass index; PBO, placebo; TZP, tirzepatide.
非 KM Figure
FIGURE 3Achievement of ≥5% weight loss at week 72 by age, sex, and BMI subgroups. The odds of achieving ≥5% body weight reduction at week 72 with tirzepatide versus placebo by (A) age; (B) sex; and (C) BMI subgroups. OR, CI, and p ‐values are from a logistic regression model using imputed data. BMI, body mass index; CI, confidence interval; N, number of participants in analysis population; n, number of participants within category; OR, odds ratio; PBO, placebo; TZP, tirzepatide.
非 KM Figure